Frequently Asked Questions about United Therapeutics Corporation (UTHR)

Name: United Therapeutics Corporation (UTHR) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does United Therapeutics Corporation (UTHR) do?

Accepted Answer

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to tre...

Question 2

Is United Therapeutics Corporation (UTHR) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of UTHR reveals an Altman Z-Score of 22.41 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($3.18B most recent), help investors decide if UTHR fits their risk profile.

Question 3

What is the current P/E ratio for UTHR?

Accepted Answer

As of the latest trading session, United Therapeutics Corporation (UTHR) has a trailing P/E ratio of 19.08.

Question 4

Who is the CEO of United Therapeutics Corporation?

Accepted Answer

The current Chief Executive Officer of United Therapeutics Corporation is Martine A. Rothblatt.

Question 5

What was UTHR's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, United Therapeutics Corporation reported annual revenues of $3.18B (2025), $2.88B (2024), $2.33B (2023), $1.94B (2022), $1.69B (2021) respectively.

Question 6

Does UTHR pay a dividend?

Accepted Answer

United Therapeutics Corporation does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does UTHR have?

Accepted Answer

In its latest reporting period, United Therapeutics Corporation generated $1.04B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of United Therapeutics Corporation?

Accepted Answer

The Price-to-Book (P/B) ratio for United Therapeutics Corporation (UTHR) is currently 3.59.

Question 9

What is the Price-to-Sales (P/S) ratio of UTHR?

Accepted Answer

Based on trailing twelve-month data, United Therapeutics Corporation (UTHR) trades at a Price-to-Sales (P/S) ratio of 7.91.

Question 10

What is United Therapeutics Corporation's Return on Equity (ROE)?

Accepted Answer

United Therapeutics Corporation (UTHR) has a Return on Equity (ROE) of 19.30%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	3.2B	2.8B	1.5B	1.3B	30.13
2024-12	2.9B	2.6B	1.4B	1.2B	26.44
2023-12	2.3B	2.1B	1.2B	984.8M	21.04
2022-12	1.9B	1.8B	979.7M	727.3M	15.98
2021-12	1.7B	1.6B	555.9M	475.8M	10.60